Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. More Details
Weak fundamentals or lack of information.
Share Price & News
How has Parnell Pharmaceuticals Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PARN.F is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 80% a week.
Volatility Over Time: PARN.F's weekly volatility has decreased from 96% to 80% over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: PARN.F exceeded the US Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: PARN.F exceeded the US Market which returned 22.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Parnell Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Parnell Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Parnell Pharmaceuticals Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Parnell Pharmaceuticals Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of PARN.F's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Parnell Pharmaceuticals Holdings regulatory filings here.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Parnell Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parnell Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of PARN.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Parnell Pharmaceuticals Holdings's filings and announcementshere.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Parnell Pharmaceuticals Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: PARN.F is currently unprofitable.
Growing Profit Margin: PARN.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PARN.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PARN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PARN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: PARN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Parnell Pharmaceuticals Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: PARN.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PARN.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PARN.F has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PARN.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PARN.F has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PARN.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Parnell Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PARN.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PARN.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PARN.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PARN.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PARN.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Brad McCarthy (44 yo)
Mr. Brad R. McCarthy, CPA, has been the Chief Financial Officer of Parnell Pharmaceuticals Holdings Ltd. since February 2010 and serves as its Chief Executive Officer since January 9, 2018 and Chief Accoun...
|Executive Chairman||14.92yrs||no data||no data|
|CEO, CFO||2.92yrs||no data||no data|
|Independent Director||2.92yrs||no data||no data|
Experienced Board: PARN.F's board of directors are seasoned and experienced ( 10.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Parnell Pharmaceuticals Holdings Ltd's company bio, employee growth, exchange listings and data sources
- Name: Parnell Pharmaceuticals Holdings Ltd
- Ticker: PARN.F
- Exchange: OTCPK
- Founded: 2009
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.128m
- Shares outstanding: 18.02m
- Website: https://www.parnell.com
Number of Employees
- Parnell Pharmaceuticals Holdings Ltd
- Century Estate
- Unit 4
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PARN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2014|
Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segme...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/04 23:28|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.